No Data
Zhejiang Huahai Pharmaceutical (600521.SH): Clinical trial applications for HB0028 injection and HB002.1T injection have been approved.
Zhejiang Huahai Pharmaceutical (600521.SH) released an announcement, stating that the company's holding subsidiary Shanghai Huadao Tai Biopharmaceutical Co., Ltd...
GF Securities Starts Zhejiang Huahai Pharmaceutical at Buy With 21.57 Yuan Price Target
Zhejiang Huahai Pharmaceutical (600521.SH): Plans to introduce investor Hai Jing Venture Capital to subscribe for an additional 20 million shares of Huaotai.
On December 25, Gelonghui reported that Zhejiang Huahai Pharmaceutical (600521.SH) announced that, in line with the company's overall development plan, to further accelerate the deployment of the Global Strategy for innovative drugs and enhance the core competitiveness and sustainable development capabilities of the company, as well as to strengthen the operational capabilities of its subsidiary Huatai, the company plans to introduce investor Haijing Venture Capital to subscribe to 20 million additional shares of Huatai. After this capital increase, Huatai's registered capital will rise from 300 million yuan to 320 million yuan, and the total share capital will increase from 300 million shares to 320 million shares.
Chinese Drug Regulator Accepts Huahai Pharma Unit's Application for Adalimumab Injection
Huahai Pharmaceutical's Two Drugs Secures Spot in China's National Drug Procurement Program
Zhejiang Huahai Pharmaceutical (600521.SH): Products are expected to be selected for the tenth batch of national pharmaceutical centralized procurement.
On December 13, Gelonghui reported that Zhejiang Huahai Pharmaceutical (600521.SH) announced that on December 12, 2024, the company participated in the bidding for the 10th batch of national drug centralized procurement organized by the National Joint Procurement Office, and the company products Apsaglerone Tablets and Sitagliptin Metformin Tablets (II) are expected to be selected for this centralized procurement.
Earnings Are Growing at Zhejiang Huahai Pharmaceutical (SHSE:600521) but Shareholders Still Don't Like Its Prospects
